摘要
他拉唑帕尼于2018年10月16日通过FDA加速审批程序批准上市,是FDA批准上市的第4个聚腺苷二磷酸核糖聚合酶[poly(ADP-ribose) polymerase,PARP]抑制剂,用于治疗有害或疑似有害生殖系BRCA突变HER2阴性局部晚期或转移性乳腺癌的成人患者。本文对他拉唑帕尼的药理作用、药动学、毒理学、临床研究、安全性等进行了归纳总结。
Talazoparib,approved under accelerated approval by the FDA on Oct 16,2018,is the fourth poly(ADP-ribose)polymerase(PARP)inhibitor approved by FDA.It is indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene-mutated(BRCA)human epidermal growth factor receptor 2(HER2)-negative locally advanced or metastatic breast cancer.This review summarizes the pharmacology,pharmacokinetics,nonclinical toxicity,clinical trials,and safety of talazoparib.
作者
黄璐
陆毅
洪怡
卢山
许勇
HUANG Lu;LU Yi;HONG Yi;LU Shan;XU Yong(Guangzhou Wellhealth Bio-Pharma Co.,Ltd.,Guangzhou 510200,China;School of Pharmacutical Sciences,Wuhan University,Wuhan 430072,China;Wuhan Xinghua Wisdom Pharma-Tech Co.,Ltd.,Wuhan 430075,China;Hubei University of Chinese Medicine Pharmacy Faculty,Wuhan 430065,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2020年第11期1211-1215,共5页
Chinese Journal of New Drugs
基金
广州开发区第二批创业英才项目(穗开组通〔2017〕16号)。
